Menu Search
Equities

Qlife Holding AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4HG0:STU

Qlife Holding AB

Actions
  • Price (EUR)0.1835
  • Today's Change0.009 / 5.16%
  • Shares traded0.00
  • 1 Year change+47.98%
  • Beta0.5752
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Qlife Holding AB is a Sweden-based medical technology Company that manufactures the hardware and software platform Egoo.health (Egoo) with which patients can carry out various types of biomarker tests based on a small amount of blood. Egoo performs analyzes that correlate to over 99 percent with high-performance laboratory instruments. The Egoo instrument measures biomarkers for the chronic diseases Phenylketonuria (PKU), rheumatoid arthritis (RA) and cancer. Qlife Holding is the parent company of the wholly owned Danish medical technology subsidiary Qlife ApS. Qlife ApS develops a medical technology product with the long-term goal of giving people access to safe and valid biomarker data at home.

  • Revenue in SEK (TTM)290.00k
  • Net income in SEK-6.28m
  • Incorporated2019
  • Employees5.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.